Roche Taps Russian HIV Opportunity With Viriom Deal

In a first-of-its kind deal, Roche recently licensed a handful of pre-clinical HIV assets to Russian biotech Viriom, a start-up created specifically to develop and commercialize the compounds in Russia, Ukraine, Belarus and Kazakhstan